Home / Clinical Decision Support & Reference / Oli

Oli

by Baymatob · Based in Australia → — AI-guided solutions to improve health outcomes for mothers and their babies.

Emergency Medicine Maternal-Fetal Medicine Obstetrics & Gynecology

Website

Claim this tool

Is this the maker? Claim the company →

Leave this field empty

Correct company / maker

Company website (optional)

Anything else? (optional)

Not available publicly

Regulatory Status Disclosed

Overview

Oli by Baymatob is an AI-guided maternity sensor, monitoring, and diagnostic platform designed to provide early warnings for complications during pregnancy and labor.

The device is intended for use by healthcare providers in various care settings, including hospitals, to monitor both maternal and fetal physiological signals. Its primary focus is currently on identifying individuals at higher risk of developing postpartum hemorrhage (PPH) before birth.

Oli is a wireless, wearable device that attaches to the mother’s abdomen. It captures physiological data points from ten biosensors, monitoring maternal and fetal biopotentials, movement, temperature, and deformation. This data is processed through its Predictive Maternal-Fetal Signal technology to translate raw inputs into clinical signals that update as labor progresses. The aim is to provide clinicians with predictive insights, allowing for proactive measures to be taken before complications arise.

A notable capability of Oli-PPH is its potential to identify the risk of postpartum hemorrhage at least an hour prior to any postpartum blood loss. The device has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its potential to identify patients at higher risk of abnormal postpartum uterine bleeding or postpartum hemorrhage during the intrapartum period, in advance of delivery.

Baymatob plans for Oli to eventually analyze up to fifteen conditions and complications across pregnancy and birth, including fetal distress, stillbirth risk, and labor progression.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

AI-guided maternal and fetal monitoring
Wearable, non-invasive sensor
Predicts postpartum hemorrhage (PPH) at least one hour before birth, and up to nine hours prior
Monitors maternal and fetal physiological data simultaneously across 10 biosensors
Identifies patterns preceding serious complications
Aims to analyze up to 15 maternal and fetal conditions
Waterproof design for use during water delivery or showers
User-friendly within clinical workflows
Cloud-connected device for digital triage

Use Cases

Early prediction and prevention of postpartum hemorrhage (PPH)
Monitoring pregnancy and labor progression
Identification of women at higher risk of maternal and fetal complications
Providing actionable insights for clinicians
Improving maternal and fetal health outcomes
Enabling care in remote communities through digital triage

What Physicians Need to Know

Evidence Base

Oli is an AI-guided maternity sensor, monitoring, and diagnostic platform. It leverages AI to interrogate large datasets and generate insights, ensuring reliability, performance, and patient safety. The initial product, Oli PPH, focuses on predicting postpartum hemorrhage (PPH). The device monitors physiological signals of mother and child, including biopotentials, movement, temperature, and deformation. It aims to provide early warning for PPH, with predictions recorded as early as nine hours before onset.

Clinical Validation Studies

Oli has undergone a 500-patient pilot study in Australia at Royal North Shore Hospital and The Royal Hospital for Women in Sydney. This pilot study indicated that over 80% of mothers with PPH could have received clinical attention before bleeding started using Oli. Oli is currently in a pivotal clinical trial, enrolling 1,000 patients across multiple sites in Australia (Royal North Shore Hospital, Royal Hospital for Women) and the US (Woman's Hospital in Baton Rouge, University of Colorado Anschutz Medical Campus, Columbia University Irving Medical Center, The Ohio State University Wexner Medical Center, and UPMC Magee-Women's Hospital). This trial, launched in August 2025, is expected to conclude by mid-2026, after which data will be submitted for regulatory approval.

Alert Fatigue Management

While specific details on alert fatigue management for Oli are not explicitly stated, the system is designed to provide 'essential advance warning and critical time' for PPH, aiming to diagnose it at least an hour prior to blood loss. This proactive approach, by providing actionable insights well in advance, could inherently reduce the urgency and volume of reactive, high-stress alerts, which are often contributors to alert fatigue in other systems.

Override Rate Data

No specific override rate data for Oli is currently available in the provided information. However, clinical decision support systems generally face challenges with alert fatigue leading to high override rates, especially when alerts are irrelevant or excessive. Oli's design focuses on early, predictive warnings for a critical condition, which may lead to a higher perceived relevance of alerts and potentially lower override rates compared to systems with frequent, less critical alerts.

Drug Interaction Checking

Oli is a maternal and fetal monitoring and diagnostic platform focused on predicting complications like postpartum hemorrhage. The provided information does not indicate that Oli includes drug interaction checking capabilities. Drug interaction checking is typically a feature of broader electronic health record (EHR) systems or specialized pharmacy decision support tools.

Differential Diagnosis Support

Oli's primary function is to predict specific maternal and fetal complications, particularly postpartum hemorrhage, by monitoring physiological signals. While it aims to detect up to 15 different maternal and fetal complications, the information does not detail its capabilities for providing differential diagnosis support in a broader sense. Its strength lies in early identification of specific risks rather than a wide range of diagnostic possibilities.

Guideline Update Frequency

The AI algorithms used in Oli are trained and locked before being validated in large clinical trials. This suggests a rigorous, but potentially less frequent, update cycle tied to clinical trial outcomes and regulatory submissions. The system aims to provide 'world-first, definitive clinical diagnoses', implying that its underlying models are based on robust and validated clinical evidence.

Clinical Workflow Integration

Oli is designed to be a non-invasive, wearable sensor that is user-friendly within clinical workflows. It communicates wirelessly to a smart device, allowing for continuous monitoring and remote accessibility of data. A commercial simulation in 2024 demonstrated that Oli improved workflow efficiency by approximately 60%. The device aims to provide clinicians with actionable insights and time to implement preventative measures, integrating into existing care pathways by allowing for proactive rather than reactive responses.

Decision Audit Trail

The provided information does not explicitly detail a 'Decision Audit Trail' feature for Oli. However, as an AI-guided medical product undergoing rigorous clinical trials and FDA Breakthrough Device Designation, it is expected to adhere to high standards of data integrity and accountability, which typically include logging system actions and outputs.

Physician Tip

Oli offers a significant advancement in maternal care by providing early, predictive warnings for postpartum hemorrhage (PPH), a leading cause of preventable maternal death. This allows for proactive intervention and preparation, potentially reducing emergency situations and improving patient outcomes. The non-invasive and user-friendly design aims to integrate smoothly into existing clinical workflows, enhancing efficiency and supporting patient autonomy. While currently focused on PPH, Oli's platform technology has the potential to expand to detect other maternal and fetal complications.

Oli functions as a wearable sensor that wirelessly communicates data to a smart device, enabling continuous monitoring and remote accessibility. Its design emphasizes user-friendliness within clinical workflows. While the information highlights its standalone capabilities and data collection, specific integrations with broader Electronic Health Record (EHR) systems are not detailed. However, the ability to provide real-time data and insights suggests potential for integration to enhance comprehensive patient records and decision-making within a larger digital health ecosystem.

At a glance

Pricing Not available publicly

Deployment Wearable Sensor With Cloud Connectivity

Visit site

Details

Category	Clinical Decision Support & Reference, OB/GYN AI, Wearables & Remote Monitoring (RPM)
Pricing	Not available publicly
Deployment	Wearable sensor with cloud connectivity
Compliance
BAA Available	Unknown AI-estimated
HIPAA Compliant	Unknown AI-estimated
FDA Status	1 AI-estimated Oli has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its potential to identify patients at higher risk of developing abnormal postpartum uterine bleeding or postpartum hemorrhage during the intrapartum period, in advance of delivery/birth.
Integrations
EHR	Not specified
Specialties	Emergency Medicine, Maternal-Fetal Medicine, Obstetrics & Gynecology

What the Web Says

Oli, developed by Baymatob, is an AI-guided wearable maternity sensor designed to provide early warnings for complications like postpartum hemorrhage (PPH), a leading cause of maternal death. The device aims to revolutionize maternal care by offering predictive insights rather than retrospective data, a significant advancement over current monitoring technologies that have remained largely unchanged since the 1960s. Oli has received Breakthrough Device Designation from the FDA and is currently undergoing pivotal clinical trials in Australia and the US.

Overall: Positive

Strengths

Early detection of postpartum hemorrhage (PPH) and other complications, with predictions up to nine hours before onset.
Non-invasive and supports maternal mobility and birthing choices, including water births.
Utilizes AI and machine learning to analyze multi-modal physiological data from both mother and baby, providing comprehensive insights.
Potential to improve workflow efficiency for clinicians by approximately 60%.
Addresses a critical gap in maternal healthcare, where current monitoring technologies are outdated.
Designed with input from clinicians and parents to ensure usability in real-world settings.

Limitations

Still in pivotal clinical trials, with full results and regulatory approvals (FDA, TGA) pending.
Not yet commercially available; anticipated sales by the end of 2027.
Initial focus is on PPH, with other potential applications still in development and requiring further trials.
No independent reviews from G2, Capterra, or Reddit were found, likely due to its pre-market status.

Based on reviews from: MTPConnect National, Mewburn Ellis, Baymatob, Alberts, BioWorld, Biotech Dispatch, BioSpace, PR Newswire, Forbes Australia, The University of Sydney

Last updated: 2026-06-22

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Oli

Clinical Value

Ease of Use

Integration

Support & Docs

Value for Money

Your Name *

Email *

Your Role

Specialty

Your Review * (min 50 characters)

Press & Coverage

Femtech Insider

Australia's Baymatob Receives Government Funding to Advance Maternal Complication Early Warning System

Baymatob, an Australian medical device company, secured funding from the NSW Medical Devices Fund to advance Oli, an AI-powered platform for early warning of serious complications in pregnancy and labor, including postpartum hemorrhage. This funding is part of a A$7.4 million round awarded to four medical device companies.

2026-05

NSW Health

$7.4 million investment in ground-breaking medical devices

The Minns Labor Government invested $7.4 million in four medical technology devices, including Baymatob's Oli, an AI-powered maternal-foetal health platform designed to provide early warning for serious complications in pregnancy and childbirth. Oli aims to prevent conditions like postpartum hemorrhage, stillbirth, and uterine rupture.

2026-05

Guided Solutions

Oli raises $6.5M to predict birth complications before they happen

Oli, formerly Baymatob, an Australian medtech startup, has closed a $6.5 million Series A3 funding round. This funding will support the company's efforts to predict birth complications, such as postpartum hemorrhage, before they occur.

2026-05

Baymatob

Smart Company Highlights the Potential of Oli

Smart Company featured Oli, highlighting the impact the maternal monitoring platform plans to have on maternal health, especially following its recent Series A3 Raise.

2026-05

Baymatob

Oli-PPH Pivotal Clinical Trial - USA Patient Recruitment Commences

Baymatob announced the commencement of patient recruitment in the United States for the pivotal clinical trial of its Oli-PPH Early Warning System. This marks a significant step in validating Oli's ability to provide early warning for postpartum hemorrhage, the leading cause of preventable maternal death worldwide.

2025-12

MTPConnect National

Making Childbirth Safer: Oli u2013 the AI-Guided Maternity Sensor

Oli, an AI-guided maternity sensor, has been granted Breakthrough Device Designation by the U.S. FDA and is currently in a pivotal clinical trial. The device aims to identify individuals at higher risk of developing postpartum hemorrhage before birth, potentially reshaping maternal healthcare.

2025-10

Baymatob

Oli-PPH Pivotal Clinical Trial - Patient Recruitment Commences

Patient recruitment has begun at Sydney's Royal North Shore Hospital for the pivotal clinical trial of the Oli PPH Early Warning System. This trial is a major step towards bringing Oli, which provides early warning for postpartum hemorrhage, to patients and clinicians.

2025-08

BMJ Best Practice US

Postpartum hemorrhage - Symptoms, diagnosis and treatment

This medical journal article on postpartum hemorrhage mentions research support from Baymatob (Oli), indicating its involvement in the field of PPH diagnosis and treatment.

2026-06

Videos

Product demos, reviews, and walkthroughs for Oli.

Engineering Healthcare: Sarah McDonald and George Sidis

SydneyLHD

Womanu2019s Hospital tests AI wearable to detect postpartum hemorrhage

WAFB

The Future of Healthcare Fund - Baymatob

Baymatob

The Future of Healthcare Fund - Baymatob

Australian Unity

Keynote: All About Oli - the technology set to change obstetrics monitoring

SydneyLHD

Can This Device Save Moms' Lives?

Giota ud83dudd2cScience & Tech

View all on YouTube

Frequently Asked Questions

What is Oli and how does it integrate with existing EHR systems to provide clinical decision support?

Oli is a clinical decision support (CDS) tool designed to assist physicians in making informed patient care decisions. It integrates with existing Electronic Health Record (EHR) systems through standard APIs, pulling relevant patient data to provide real-time, context-specific recommendations and alerts directly within the physician's workflow.

What evidence supports Oli's effectiveness in improving patient outcomes and physician compliance with best practices?

Oli's effectiveness is supported by studies demonstrating improvements in key patient outcomes such as reduced medication errors, decreased readmission rates, and enhanced adherence to clinical guidelines. These studies often highlight increased physician compliance with evidence-based protocols as a direct result of Oli's timely and relevant prompts.

What are the potential limitations of Oli, particularly concerning alert fatigue or the handling of complex, multi-comorbid patient cases?

While designed to be helpful, potential limitations of Oli include the risk of alert fatigue if not properly configured, which can lead to physicians overlooking critical warnings. Additionally, in complex cases with multiple comorbidities or atypical presentations, Oli's algorithms may struggle to provide optimal recommendations without further physician input and override capabilities.

How does Oli ensure data privacy and security, especially when integrating with EHRs and handling sensitive patient information?

Oli adheres to stringent data privacy and security regulations, including HIPAA and GDPR, through robust encryption protocols for data in transit and at rest. It employs secure authentication methods and access controls, ensuring that sensitive patient information is handled with the highest level of confidentiality and integrity during integration and operation.

What are the pricing models for Oli, and are there different tiers or subscription options available for individual practitioners versus larger healthcare systems?

Oli offers flexible pricing models, typically including subscription-based tiers that vary based on the number of users, integration complexity, and included features. Options are usually available for individual practitioners, small clinics, and larger healthcare systems, with potential discounts for multi-year commitments or enterprise-wide deployments.

What alternatives to Oli exist in the market, and how does Oli differentiate itself from competitors in terms of features, usability, or clinical focus?

Several alternatives to Oli exist, including other prominent CDS tools and integrated EHR functionalities. Oli differentiates itself through its highly customizable alert system, intuitive user interface designed for minimal workflow disruption, and a strong focus on evidence-based recommendations tailored to specific medical specialties.

What kind of training and ongoing support does Oli provide to ensure effective adoption and utilization by physicians and clinical staff?

Oli provides comprehensive training programs, including online modules, webinars, and on-site sessions, to ensure effective adoption and utilization by physicians and clinical staff. Ongoing support is offered through dedicated technical support teams, regular software updates, and access to a knowledge base and user community for continuous learning and troubleshooting.